Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 12/20 | 0.60 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.60 |
| ▸ | FPR2 | P25090 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167025 | 0.94 | HCRTR2 (0.58) | HCRTR2HCRTR1FPR2TSHRALDH1A1 | |
| SCHEMBL1166379 | 0.91 | HCRTR2 (0.58) | HCRTR2HCRTR1FPR2TSHRALDH1A1 | |
| SCHEMBL1166977 | 0.91 | HCRTR2 (0.58) | HCRTR2HCRTR1FPR2TSHRALDH1A1 | |
| SCHEMBL1166557 | 0.91 | HCRTR2 (0.58) | HCRTR2HCRTR1FPR2TSHRALDH1A1 | |
| SCHEMBL1166019 | 0.91 | HCRTR2 (0.61) | HCRTR2HCRTR1FPR2TSHRALDH1A1 | |
| SCHEMBL1166694 | 0.91 | HCRTR2 (0.72) | HCRTR2HCRTR1FPR2MEN1KMT2A | |
| SCHEMBL1166206 | 0.90 | HCRTR2 (0.60) | HCRTR2HCRTR1FPR2TSHRALDH1A1 | |
| SCHEMBL1166243 | 0.90 | HCRTR2 (0.60) | HCRTR2HCRTR1FPR2TSHRALDH1A1 | |
| SCHEMBL1165969 | 0.90 | HCRTR2 (0.56) | HCRTR2HCRTR1FPR2TSHRALDH1A1 | |
| SCHEMBL1166987 | 0.90 | FPR2 (0.68) | HCRTR2HCRTR1FPR2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | claimed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | HCRTR2 2700/4885HCRTR1 2862/4885FPR2 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.